Clinical Trial Update: A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ITCA 650 as add-on therapy to glimepiride for type 2 diabetes has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Glimepiride (glimepiride)
• ITCA 650

Snippet

Sponsor: Intarcia Therapeutics | Conditions: Type 2 Diabetes | Phase 3 | Status: WITHDRAWN